NEW YORK, August 2, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please
scroll to bottom.
Today, Investors' Reports announced new research reports
highlighting Stereotaxis Inc. (NASDAQ: STXS), Arena
Pharmaceuticals, Inc. (NASDAQ: ARNA), USANA Health Sciences, Inc.
(NYSE: USNA), NuVasive, Inc. (NASDAQ: NUVA), and MAKO Surgical
Corp. (NASDAQ: MAKO). Today's readers may access these reports free
of charge - including full price targets, industry analysis and
analyst ratings - via the links below.
Stereotaxis Inc. Research Report
On July 29, 2013, Stereotaxis Inc.
(Stereotaxis) announced that it has been granted 510(k) clearance
by the Food and Drug Administration (FDA) to market its
Vdrive Robotic Navigation System with V-Sono Intracardiac
Echocardiography (ICE) catheter manipulator in the U.S. According
to Stereotaxis, the Vdrive with V-Sono system is
indicated for the remote control of compatible ICE (or ultrasound)
catheters inserted into the right atrium. Stereotaxis said that the
Vdrive, with V-Sono system, can improve efficiency for a
Niobe ES remote magnetic navigation procedure by enabling a
single-operator workflow through eliminating the need for manual
ICE manipulation inside the sterile and radiation field.
William Mills, Stereotaxis Board
Chairman and Interim CEO, said, "The Vdrive platform has
added significant clinical value to a growing number of Niobe ES
labs in Europe, and this V-Sono
clearance should accelerate procedure growth in our U.S. installed
base as well as open up an untapped, expanding electrophysiology
(EP) market where ICE catheters are widely utilized." The Full
Research Report on Stereotaxis Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.analystscorner.com/r/full_research_report/b071_STXS]
--
Arena Pharmaceuticals, Inc. Research
Report
On July 25, 2013, Arena
Pharmaceuticals (Arena) announced that its wholly owned subsidiary,
Arena Pharmaceuticals GmbH, has entered into an exclusive marketing
and supply agreement with CY Biotech Company Ltd. (CYB) for BELVIQ
(lorcaserin HCl) in Taiwan. Arena
said that it granted CYB the rights to market and distribute BELVIQ
in Taiwan for weight loss or
weight management in obese and overweight patients, subject to
regulatory approval of BELVIQ by the Taiwan Food and Drug
Administration (TFDA). Further, Arena informed that it will
manufacture BELVIQ in Switzerland
and sell the finished product to CYB for a purchase price of 45% of
CYB's annual net sales. The Company also reported receiving a net
upfront payment of $2 million, and is
eligible to receive purchase price adjustment payments based on
CYB's annual net sales, as well as a milestone payment upon
approval of the first additional indication for BELVIQ by the TFDA.
The Full Research Report on Arena Pharmaceuticals, Inc. - including
full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/6a95_ARNA]
--
USANA Health Sciences, Inc. Research
Report
On July 23, 2013, USANA Health
Sciences Inc. (USANA) announced that it has been accepted as one of
the 52 dedicated Direct Selling Association member companies to
participate in the 2013 DSA Code of Ethics Communication
Initiatives. Dan Whitney, USANA Vice
President of Ethics and Market Expansion, said, "The direct-selling
business model is often misunderstood, which is why USANA works
tirelessly to distinguish itself as an ethical and transparent
company. Because USANA is publicly traded, it's important to us
that we demonstrate our commitment to the highest level of ethics
in our financial reporting, scientific research and in the way our
employees are treated. Being accepted to this initiative is a
testament of USANA's commitment to ethical business practices and
consumer service." The Company reported that it was recognized with
this award by the DSA for the fourth consecutive year. The Full
Research Report on USANA Health Sciences, Inc. - including full
detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/ee40_USNA]
--
NuVasive, Inc. Research Report
On July 30, 2013, NuVasive, Inc.
(NuVasive) reported its financial results for Q2 2013. Revenue
increased 7.3% YoY to $165.7 million.
Net loss attributable to NuVasive was $6.5
million or $0.15 per share in
Q2 2013, compared to a net income of $2.9
million or $0.06 per diluted
share in Q2 2012. Commenting on the results, Alex Lukianov, Chairman and CEO of NuVasive,
said, "Results in the first half of 2013 demonstrate solid
execution against a multi-year plan, and give us increased
confidence in our ability to execute to the full year guidance we
have outlined." He added, "NuVasive is changing spine surgery with
a proven, share taking strategy of Superior Outcomes, Absolute
Responsiveness, and Speed of Innovation. That mission will drive
our evolution toward $1 billion in
revenue with an improved profitability profile." The Full Research
Report on NuVasive, Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free
of charge at:
[http://www.analystscorner.com/r/full_research_report/c66c_NUVA]
--
MAKO Surgical Corp. Research
Report
On July 30, 2013, MAKO Surgical
Corp. (MAKO) reported its financial results for Q2 2013. Revenue
grew 19.2% YoY to $28.2 million. Net
loss was $19.7 million or
$0.42 per diluted share, in Q2 2013
compared to net loss of $8.5 million
or $0.20 per diluted share in Q2
2012. Commenting on the results, Maurice R. Ferré, M.D., President
and CEO of MAKO, said, "We are pleased that our programs
implemented in the first quarter to drive utilization and system
sales are beginning to show positive business results.
Additionally, the recently released favorable data on both knee and
hip MAKOplasty provides continuing support for the clinical value
proposition of our procedures." The Full Research Report on MAKO
Surgical Corp. - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/7465_MAKO]
----
EDITOR NOTES:
- This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a
best efforts basis and reviewed by a CFA. However, we are only
human and are prone to make mistakes. If you notice any errors or
omissions, please notify us below.
- This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
- If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us
at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar
coverage on your company? Send us a full investors' package to
research@EquityNewsNetwork.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is prepared and authored by
Equity News Network. An outsourced research services provider has,
through Chartered Financial Analysts, only reviewed the information
provided by Equity News Network in this article or report according
to the Procedures outlined by Equity News Network. Equity News
Network is not entitled to veto or interfere in the application of
such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as
to the accuracy or completeness or fitness for a purpose
(investment or otherwise), of the information provided in this
document. This information is not to be construed as personal
financial advice. Readers are encouraged to consult their personal
financial advisor before making any decisions to buy, sell or hold
any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may
be occasioned at the time of printing of this document or any
error, mistake or shortcoming. No liability is accepted by Equity
News Network whatsoever for any direct, indirect or consequential
loss arising from the use of this document. Equity News Network
expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance
placed on the information in this document. Equity News Network
does not (1) guarantee the accuracy, timeliness, completeness or
correct sequencing of the information, or (2) warrant any results
from use of the information. The included information is subject to
change without notice.
InvestorsReports.com
SOURCE Investors' Reports